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Primary photodynamic therapy for pigmented posterior pole cT1a choroidal 
melanoma resulted in the present cohort of 26 patients (26 eyes) with 62% success 




Aims: To investigate the outcomes of primary photodynamic therapy (PDT) for 
pigmented posterior pole cT1a choroidal melanoma.  
Methods: Retrospective interventional consecutive case series of 26 patients (26 
eyes) with pigmented posterior pole cT1a choroidal melanoma, who were treated 
with 3 sessions of PDT and followed-up thereafter.  
Results: Included were 11 males and 15 females that presented at a median age of 
66 years (mean: 64) with transformed naevi (n=11) or suspicious lesions (n=15) with 
≥3 risk factors for growth, with lipofuscin in all. In all cases, diagnosis was clinically 
based (no tissue biopsy). Tumour control was achieved in 16 (62%) patients in a 
median follow-up time of 29 months (mean: 27). Ten patients failed treatment by 
form of radial expansion, diagnosed in a median time of 13 months (mean: 12) from 
last treatment. By Kaplan-Meier analysis, success rate after 1, 2 and 3 years was 85%, 
59% and 51%, respectively. On statistical analysis, number of suspicious features was 
found to be the only risk factor predicting failure (p=0.046). One patient developed 
macula-sparing branch retinal artery occlusion after treatment. Following PDT, 
subretinal fluid resolved in all cases and visual acuity significantly improved in all 
treatment-success cases (p=0.043). There were no cases of metastatic spread.  
Conclusion: Primary PDT resulted in tumour regression of small, pigmented 
choroidal melanoma in 62% after a mean of 27 months. Treatment was more 
effective in tumours with 3 or less risk factors for growth, and resulted with fluid 




Uveal melanoma is the most common primary intraocular malignancy in adults and 
choroidal melanoma is the most common subtype.[1] The American Joint Committee 
on Cancer (AJCC) classifies uveal melanomas according to several variables, including 
tumour size, location, presence or absence of extraocular extension, and serves as a 
prognostic tool.[2] Those features that comprise the AJCC scheme are also used to 
guide primary treatment. For choroidal melanoma, eyes classified as cT3-4 
commonly undergo primary enucleation, although conservative therapy was 
attempted,[3–5] with variable results. cT2 and the larger spectrum of cT1 (3.1-
6.0mm in thickness) cases are primarily treated in most centres by means of local 
radiotherapy,[6] whether plaque or proton beam radiotherapy. For the smallest 
choroidal melanoma category, cT1a with tumours ≤3mm in thickness, and especially 
the borderline cases (i.e. suspicious naevi),[7] there is however no consensus 
regarding the preferred management choice. While some advocate early treatment 
with local radiotherapy, in order to reduce the chances for adverse cytogenetic 
alterations[8] and lower the risk of metastatic spread,[9] others are reluctant to treat 
small lesions with only suspicious features but no evidence of tumour growth, and 
especially when patients are visually asymptomatic, as radiotherapy is associated 
with vision deterioration in over 50% of cases.[10] 
 
Over the years, before and during the local radiotherapy era, several laser-based 
modalities were tested for small choroidal melanoma, including photocoagulation, 
transpupillary thermotherapy and photodynamic therapy (PDT). While the prior two 
were abandoned as primary treatment due to relatively high recurrence rate,[11,12] 
PDT was reported to result with high tumour control rate when used in both 
pigmented and non-pigmented choroidal melanomas.[13,14] In the London Ocular 
Oncology Service, PDT with verteporfin has been used since 2014 for selected cases 
of choroidal melanoma. Our group recently published the short-term results of 
primary PDT used in 15 patients with small (T1a) posterior pole choroidal melanoma, 
where all tumours were pigmented.[15] In a short follow-up time of 15 months, 
tumour control was achieved in 80% of cases, no complications were recorded and 
visual acuity (VA) improved. In the present study, we aimed to investigate the safety 
and efficacy of PDT with verteporfin for clinically diagnosed pigmented posterior 




The study was performed in a retrospective manner and approved by the Moorfields 
Eye Hospital institutional review board in concordance with the declaration of 
Helsinki. All patients with pigmented posterior pole T1a choroidal melanoma that 
presented to the London Ocular Oncology Service from April 2014 to December 
2015, were treated with PDT with verteporfin, and followed-up thereafter, were 
included in the study. Of the study cohort, 15 patients (15 eyes) which were reported 
previously following a median follow-up time of 15 months,[15] were also included 
and reported herein with extended follow-up.  
 
To be included in the study, tumours had to be pigmented in at least 50% of their 
surface area, have thickness of less than 3mm and either demonstrate documented 
recent growth (i.e. malignant transformation or transformed naevus), or to have at 
least 3 risk factors for growth. The established risk factors for growth are as follows: 
lesion thickness >2mm, presence of subretinal fluid, presence of lipofuscin, related 
symptoms or margin to optic disc ≤3mm.[16] For the suspicious naevi subgroup, the 
presence of lipofuscin was defined as prerequisite sign, to differentiate leaking naevi 
from early melanoma. Patients were also offered alternative radiotherapy (i.e. 
plaque brachytherapy or proton beam radiotherapy) or an option of close 
monitoring with no intervention, according to the clinical scenario, and advantages 
and disadvantages of each treatment option was discussed. As part of the prior 
interventional radiotherapy option, all patients were offered to undergo tissue 
biopsy for definite diagnosis and prognostication.   
 
All patients underwent a full ophthalmic evaluation at each appointment, including 
slit lamp bimicroscopy, colour fundus photography, autofluorescence imaging, 
enhanced depth imaging optical coherence tomography of the lesion and fovea and 
B-scan ultrasonography.  
 
Prior to PDT, written consent was obtained, after patients were informed regarding 
the possible risks, benefits and potential short-term success rate associated with 
PDT.[15]  
 
Treatment protocol included an infusion of verteporfin (Visudyne, Novartis, UK), 6mg 
per m2 body surface area of over 10 minutes. Five minutes after infusion completion, 
laser treatment commenced. Parameters were set to a light dose of 50J/cm2, power 
density of 600mW/cm2, double duration treatment time (83 sec x 2) and spot size to 
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cover the entire lesion. Where the basal diameter of the tumour was greater than 
the maximal spot size, multiple confluent spots were used. Following treatment, 
patients were instructed to avoid exposure to direct light for 48 hours. Altogether, 
patients received 3 PDT sessions, 4-8 weeks apart, and were closely monitored 
thereafter, once every 3 months. Treatment failure was defined as tumour growth in 
diameter, height, or both, following PDT. All patients underwent systemic staging at 
diagnosis, received shared care with a medical oncologist and were enrolled in our 
metastatic surveillance program with 6 monthly abdominal ultrasound scans. 
Patient data retrieved from medical charts included sex, age, race, past ocular and 
medical history, visual acuity and the presence of symptoms. Tumour characteristics 
recorded included location, height and maximum diameter on B scan ocular 
ultrasound, the presence or absence of subretinal fluid, and the degree of 
pigmentation. Treatment parameters were recorded and the interval between 
treatments was specified. Tumour response and ocular complications were 
recorded. Length of follow up, defined from the first PDT treatment to the last follow 
up visit in clinic, was noted. 
 
Statistical Analysis 
Calculations and plotting were done using the R Statistical Environment.[17] 
Continuous variables were evaluated with Student t tests and categorical variables 
with Fisher's Exact Test or Wilcoxon Rank-sum Test. Kaplan-Meier Survival Estimate 
curves were used to predict non-failure rate. P-value<0.05 was considered 
significant. Risk factors for treatment failure were analyzed by means of univariate 
analysis and significant factors were included in a multivariate analysis. Snellen visual 
acuity (VA) was converted to logMAR equivalent. Approximations for VA worse than 
20/400 were as follows: counting fingers, 20/2000; hand motions, 20/4000; light 




Twenty-six patients (26 eyes), 11 (42%) males and 15 (58%) females that presented 
at a median age of 66 years (mean; 64, range: 32-89), fulfilled the inclusion criteria 
for the study and they comprise the study cohort. Tables 1 and 2 depict the 
demographic and clinical features of the study patients at presentation. Eleven (42%) 
of the patients were diagnosed with a transformed naevus due to documented 
growth (Figure 1) after a median follow-up time in our service of 61 months (mean: 
67; range: 44-193), prior to transformation. The remaining (58%) patients had a 
suspicious pigmented choroidal lesion with a median number of 4 risk factors for 
growth (mean: 4; range: 3-5). Of the tumours, 23 (89%) were ≤2mm in elevation and 
in 23 (89%) of the eyes subretinal fluid was present.  
Table 1. Primary photodynamic therapy with verteporfin for pigmented cT1a choroidal melanoma in 
26 patients: Patients demographic and clinical features at presentation.  
Variable Number Percentage 
Age (years) 
          Median (mean, range) 
 
66 (64, 32-89) 
 
Gender 
          Male  








          Right 







LogMAR tumour eye 
          Median (mean, range) 
 








Number of risk factors for growth  0 – 1 
1 – 1 
2 – 2 
3 – 7 
4 – 13 







Tumour dimensions (mm) 
          Median (mean, range) 
                    Height 
                    Base 
 
 
1.3 (1.4, 0.9-2.7) 
5.1 (5.4, 3.0-8.9) 
 
Distance of tumour from (mm): 
          Median (mean, range) 
                    Optic disc 
                    Fovea 
 
 
2.0 (2.0, 0.0-9.0) 
1.0 (1.6, 0.0-4.5) 
 
Presence of subretinal fluid: 
         General 







Tumour pigmentation   
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          Full 





* Patients with at least 3 risk factors for growth (from the following: lesion thickness >2mm, presence 
of subretinal fluid, presence of lipofuscin, related symptoms or margin to optic disc ≤3mm).7 Presence 
of lipofuscin was considered a prerequisite, to differentiate cases of early choroidal melanoma from 
leaking naevi.  
Table 2. Primary photodynamic therapy with verteporfin for pigmented cT1a choroidal melanoma in 26 patients: Presentation details per patient and 










(# risk factors) 
Tumour height 
(mm) 





1st PDT (months) 
1* 66 F L 0.24 Suspicious (4) 1.8 2.5 0 36 
2 56 F R -0.08 Transformed (3) 0.9 0.5 4 38 
3* 60 M L 0 Suspicious (4) 0.9 0.5 0 32 
4* 32 F R 0.18 Suspicious (4) 0.9 0 0 30 
5 70 F L 0.08 Suspicious (3) 1.1 0 3 36 
6 80 M L 0.18 Transformed (1) 1.1 3.5 2.5 29 
7 66 F R 0.3 Transformed (0) 1.5 5 3 31 
8 44 F L -0.08 Suspicious (4) 1.2 2.5 0.5 38 
9* 78 F R 0.18 Suspicious (5) 2.7 1 4 35 
10* 53 M R 0.18 Transformed (4) 1 0 0 33 
11 81 M R 0 Suspicious (3) 1 0 1.5 39 
12 74 F L 0.2 Suspicious (4) 0.9 1.5 0.5 19 
13 41 F R 0.18 Transformed (3) 1.65 0 3.5 36 
14 62 F R 0.3 Suspicious (4) 1.2 3 1 35 
15* 80 M L 0.48 Suspicious (4) 1.5 0 2 29 
16 63 F L 0 Transformed (2) 1.4 9 4 24 
17* 53 M L 0.176 Suspicious (3) 1.3 4.5 1 26 
18 89 M R 0 Transformed (3) 1 2.5 0.5 17 
19* 80 M R 0 Transformed (4) 2 4.5 1.5 24 
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20 54 F R 0.301 Suspicious (4) 1.1 2.5 1 20 
21 66 M R 0.301 Transformed (4) 2.2 2.5 0 22 
22* 77 F R 0.301 Transformed (2) 1.3 3 0.5 9 
23 50 M L 0.176 Suspicious (4) 1.66 0 2 18 
24 66 F R 0 Suspicious (4) 1.6 0 4.5 19 
25 76 M L 0 Transformed (3) 1.8 3 1 20 
26* 55 F L 0.477 Suspicious (5) 2.4 1 0 19 
* Failure 
** Suspicious naevus: patients with at least 3 risk factors for growth (from the following: lesion thickness >2mm, presence of subretinal fluid, presence 
of lipofuscin, related symptoms or margin to optic disc ≤3mm).7 Presence of lipofuscin was considered a prerequisite, to differentiate cases of early 
choroidal melanoma from leaking naevi. Transformed: naevus with documented tumour growth.  
F: female, M: male, L: left eye, R: right eye, PDT: photodynamic therapy 
All patients (100%) received 3 sessions of PDT with a median interval between 
sessions of 56 days (mean: 51; range: 28-79). No procedural complications were 
recorded during or after PDT, but a single patient that noticed a visual field defect 
one day after treatment, and was diagnosed with macula sparing branch retinal 
artery occlusion.  
 
At a median follow-up time of 29 months (mean: 27; range: 9-39) from first PDT 
session (Table 2), tumour control was achieved in 16 (62%) of the cases. By Kaplan-
Meier analysis (Figure 2), success rate after 1 and 2 years was 85% and 59%, 
respectively, and after 3 years was 51% (Standard Error: 0.12; 95% Confidence 
Intervals: 26%-72%).  
The remaining 10 (38%) cases showed tumour growth, despite PDT. The median time 
to detect treatment failure was 13 months (mean: 12; range: 1-26) from last 
treatment. In all treatment failure cases, tumours showed a radial expansion pattern 
(Figure 3), 2 (20%) of the 10 tumours also demonstrated an increase in elevation. 
 
All uncontrolled tumours (n=10) received second line treatment. Second line 
therapies included proton beam radiotherapy (n=3), plaque brachytherapy (n=8) and 
secondary PDT (n=2). Of note, 3 of the 10 uncontrolled tumours (30%) required third 
line treatment. These tumours received successful third line proton beam 
radiotherapy following failure of second line plaque brachytherapy, plaque 
brachytherapy following failure of second line PDT and one eye was enucleated 
following failure of second line plaque brachytherapy. 
 
The results of the univariate analysis of risk factors for PDT failure are shown in Table 
3.  The presence of subfoveal fluid (p=0.051), related symptoms (p=0.087) and 
distance to fovea (p=0.053) showed a statistical trend towards significance. 
However, only total number of suspicious features, analyzing both cases of 
transformed and suspicious lesions, was found to be a significant risk factor for PDT 
failure (p=0.046). On calculation, odds ratio for treatment failure following PDT was 
2.1 for tumours manifesting 3 or more risk factors for growth and 5.1 for tumours 
manifesting 4 or more risk factors for growth. Multivariate analysis was not 
executed, as only a single variable was found to be significant on univariate analysis.  
Table 3. Primary photodynamic therapy with verteporfin for pigmented cT1a choroidal 
melanoma in 26 patients: Univariate analysis for treatment failure (n=10) 
Variable  P value 
Age at presentation (median (mean; range))  




 Non-Failures: 65.5years (64.9; 40.8-89.0) 
Gender  
Failures: 5/10 Male 
 Non-Failures: 6/16 Male 
0.69 
Etiology (Suspicious vs. transformed naevus) 
Failures: 7/10 suspicious  
 Non-Failures: 8/16 suspicious 
0.43 
Laterality  
Failures: 5/10 Right 
 Non-Failures: 9/16 Right 
0.99 
LogMAR acuity at presentation (median (mean; range)) 
Failures: 0.2 (0.2; 0.0-0.5) 
 Non-Failures: 0.1 (0.1; -0.1-0.3) 
0.11 
Presence of any SRF   
Failures: 10/10 Yes 
 Non-Failures: 13/16 Yes 
0.051 
Ocular Symptoms 
Failures: 9/10 Yes 
 Non-Failures: 8/16 Yes 
0.087 
Presence of Lipofuscin   
Failures: 9/10 Yes 
 Non-Failures: 14/16 Yes 
0.99 
Distance to Optic Nerve head (median (mean; range))  
Failures: 1.0mm (1.7; 0.0-4.5) 
 Non-Failures: 2.5mm (2.2; 0.0-9.0) 
0.53 
Distance to Optic Nerve head (Categorical Variable) 
Failures: 8/10 Closer than 3mm 
 Non-Failures: 13/16 Closer than 3mm 
0.99 
Distance to Fovea (median (mean; range)) 
Failures: 0.3mm (0.9; 0.0-4.0) 
 Non-Failures: 2.0mm (2.1; 0.0-4.5) 
0.053 
Tumour Height at presentation (median (mean; range)) 
Failures: 1.4mm (1.6; 0.9-2.7) 
 Non-Failures: 1.2mm (1.3; 0.9-2.2) 
0.28 
Largest Basal Diameter at presentation (median (mean; range)) 
Failures: 5.4mm (5.7; 3.0-8.9) 
 Non-Failures: 5.1mm (5.3; 3.5-6.9) 
0.54 
Full or mixed pigmentation 
Failures: 7/10 Full 
 Non-Failures: 12/16 Full 
0.99 
Total number of risk factors*(median (mean; range)) 
Failures: 4.0 (3.9; 2.0-5.0) 
 Non-Failures: 3.0 (3.1; 0.0-4.0) 
0.046 
* Lesion thickness >2mm, presence of subretinal fluid, presence of lipofuscin, related 
symptoms or margin to optic disc ≤3mm.  
 
In all (100%) cases, including those that had treatment failure, subretinal fluid was 
totally eliminated following PDT. Median final logMAR of the treatment success 
group was 0.00 (mean: 0.04; range: -0.08-0.18). At presentation, median logMAR for 
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this subgroup was 0.13 (mean: 0.12; range: -0.08-0.30), significantly worse than after 
PDT (p=0.043).  
 
None of the patients developed distant metastasis during follow-up and all were 





In this study, Primary PDT with verteporfin for small pigmented posterior pole cT1a 
choroidal melanoma resulted in tumour control in only 62% of cases at 2.5 years. In 
comparison, 86% tumour control rate was reported following iodine plaque 
radiotherapy for juxtapapillary choroidal melanoma,[19] and 88% and 94% following 
ruthenium plaque radiotherapy and proton beam radiotherapy for choroidal 
melanoma, respectively.[20,21] In the present study, increased number of risk 
factors for growth[7] was found to be the only significant factor to predict failure, 
with odds ratio of 5.1 for tumours with 4 or more risk factors. We conclude that PDT 
for small pigmented choroidal melanoma may be more effective in tumours with 
fewer risk factors for growth, particularly in patients that are unfit for surgery. Given 
these results it is more appropriate to offer the most suspicious tumours, with 4 or 
more risk factors, local radiotherapy treatments in the form of plaque 
brachytherapy, proton beam radiotherapy or stereotactic radiosurgery, despite their 
risk of loss of vision.  
 
In the absence of a biopsy-proven diagnosis, one may argue that PDT failed in the 
genuine melanoma cases with more suspicious features (risk factors for growth), and 
was successful in the naevi cases with less suspicious features. However, it should be 
noted that of the 16 tumours successfully controlled with PDT, 8 (50%) 
demonstrated relatively rapid tumour growth before treatment. In the absence of 
biopsy, the majority of Ocular Oncologists would use growth in a short period of time 
to confirm a diagnosis of choroidal malignant melanoma. In the remaining 8 cases, 6 
(75%) had 4 risk factors for growth, reflecting cases that are selected for treatment 
in specialist centres. Fine needle aspiration biopsy (FNAB) is usually performed for 
prognostication of uveal melanoma at the time of treatment.[22,23] Very few Ocular 
Oncologists currently biopsy tumours to make a diagnosis, as clinical examination 
combined with ultrasound are sufficient in the majority of cases.[24,25] In addition, 
the potential risk of visual complications following FNAB are greater for tumours 
located at the posterior pole.  
 
In our previous report on short-term outcomes of PDT for small posterior pole 
choroidal melanoma,[15] all 3 failed cases occurred in a relatively narrow time frame 
(3-6 months) after treatment and were thereafter immediately and successfully 
treated with secondary local radiotherapy. In the present study, of the 10 failed 
cases, 3 (30%) had to undergo an additional treatment after secondary line, one of 
which was enucleation. The median interval between completion of treatment and 
local relapse was 13 months in the present study, indicating that close follow up for 




Similar to our initial results,[15] here too, in a larger cohort, the failure pattern was 
of radial tumour growth in all cases, although in 2, an increase in elevation was also 
noted. Interestingly, PDT with verteporfin has been found to be effective in small 
amelanotic melanomas.[26] However, it has been speculated that PDT is ineffective 
for pigmented choroidal melanoma because pigment might block penetration of the 
laser,[27,28, 29] likely resulting with radial growth of the deeper undamaged 
malignant cells. From a mechanistic perspective, PDT with verteporfin is believed to 
cause damage to cellular components by the formation of free oxygen radicals,[30] 
hence dependent on laser-tissue penetration. However, verteporfin may also have a 
role, independent of its activation by PDT, as an anticancer compound associated 
with the Hippo pathway.[31] In this study, the independent and possibly additive 
actions of PDT and verteporfin were nevertheless found to be insufficient in 
controlling the tumours in 10 of the cases.  
  
PDT was found to be useful in eliminating overlying subretinal fluid in all cases, 
resulting with improved VA in the non-failed cases. These results are in agreement 
with a previous report, which showed its beneficial outcome in resolving subretinal 
fluid in choroidal naevi cases.[32]  
 
PDT is considered generally a safe treatment modality, although some ocular 
complications were reported in association with its use, including transient visual 
disturbances, choroidal atrophy, vitreous hemorrhage, exudative retinal 
detachment,[30] and also a case of branch retinal artery occlusion.[33] Although rare, 
patients should be informed of the possibility of sight-threatening complications 
which has immediate negative visual consequences. In contrast, the alternative 
treatments with standard radiotherapy for uveal melanoma carry a much greater 
incidence of visual loss for posterior pole choroidal melanoma albeit many years 
later. Serious, non-ocular, adverse events were also reported following PDT, likely in 
relation to exposure to verteporfin, including anaphylactoid reaction, syncope, and also 
a case of cerebrovascular accident.[34–36] However, all were reported to occur during 
or immediately after verteporfin infusion, unlike the patient from the present series 
that died of stroke 8 months following treatment.  
 
This study was partly based on a retrospective chart review, hence had inherent 
limitations in respect to data collection. However, nearly 60% of the patients 
included in the present cohort were previously reported in a prospective study,[15] 
allowing collection of full and detailed clinical variables. Similarly, full clinical details 
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were also available for the remaining patients that were not included in the initial 
report. In terms of cohort size, this study is based on a relatively small sample; 
however, it is currently the largest found in the literature on PDT for choroidal 
melanoma in general and specifically pigmented melanomas.  
 
In summary, while management algorithms are relatively straightforward for large 
and medium-sized choroidal melanomas in terms of both when and how to treat, for 
small choroidal lesions suspected to be early melanomas this is not the case. For the 
latter, current management options include careful observation versus local 
radiotherapy, which is associated with vision loss in many of the cases.[37] PDT with 
verteporfin for posterior pole pigmented cT1a choroidal melanomas may have a 
potential role in this scenario. It resulted with significant reduction in fluid, but only 
62% success rate after less than 3 years, which is a concern, especially as longer 
follow-up is desired. If PDT with verteporfin is used as a primary treatment for 
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A fundus image of a suspicious choroidal naevus with overlying orange pigment as 
the sole risk factor for growth (A). After 10 years of follow-up the tumour has 
increased in its dimensions (B) and overlying fluid was noticed (C), as evidence for 





Kaplan-Meier estimate for success. success rate after 1 and 2 years was 85% and 
59%, respectively, and after 3 years was 51% (Standard Error: 0.12; 95% Confidence 





A fundus image of a small T1a choroidal melanoma (A) with overlying subretinal fluid 
(B), also over the fovea (C). Eighteen months following primary PDT, the tumour 
have transformed into a scar (D, arrow), but a small area of radial expansion 
(arrowhead). There was no evidence of overlying subretinal fluid (E and F). The 
patient was treated with secondary PDT and followed-up for additional 6 months 
with good tumour control. 
  
